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Abstract : Background : The aim of this study was to investigate quality of life (QOL) and night-time sleep dis-
turbance in colon cancer patients with middle risk chemotherapy for proper antiemetic therapy. Methods : The 
study enrolled 139 patients with colorectal cancer. All patients received oxaliplatin or irinotecan-based che-
motherapy. Patients completed a questionnaire about chemotherapy-induced nausea and vomiting and sleep 
disturbance. Sleep disturbance was checked, and the relationship between sleep disturbance and nausea was an-
alyzed. Results : The prevalence of nausea was 48.9% (68 / 139). The degree of the nausea was slight / moderate / se-
vere in 51 / 11 / 6 patients, and 12 patients had vomiting. Appetite showed no change / slightly decreased / half / one-
fourth / none in 51 / 34 / 33 / 6 / 7 patients. There were significant differences in the mental component summary 
(MCS) score and the role-social component score (RCS). (MCS : nausea(+) vs nausea(-) 46.4 ± 1.1 vs 54.1 ± 1.1 p < 0.01 
RCS : nausea(+) vs nausea(-) 33.1 ± 2.1 vs 41.6 ± 2.1 p < 0.01). Using the MCS with a cut-off score of 50, patients were 
divided into two groups, and nausea was significantly correlated with a low MCS score. Furthermore, patients 
were divided into two groups using a Pittsburgh Sleep Quality Index cut-off score of 6, and sleep disturbance was 
correlated with old age and second-line chemotherapy. Conclusions : Nausea affects QOL and night-time sleep of 
colon cancer patients with middle risk chemotherapy. J. Med. Invest. 67 : 338-342, August, 2020
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INTRODUCTION
 
Nausea and vomiting are frequent adverse events of cancer 
chemotherapy. Persistent nausea and vomiting are accompa-
nied by decreased food and fluid intake, leading to dehydration, 
electrolyte abnormalities, weight loss, poor nutrition etc., which 
markedly decrease the patient’s quality of life (QOL). Therefore, 
it is very important to control and minimize nausea and vomit-
ing to enable continuation of cancer chemotherapy (1).
Despite the use of antiemetic prophylaxis, cancer patients ex-
perience significant chemotherapy-induced nausea and vomiting 
during 30% to 45% of cycles, which reduces their QOL. Among 
the risk factors for chemotherapy-induced nausea and vomiting 
(CINV), younger age, female sex, low alcohol consumption, and 
pregnancy-associated emesis or motion sickness are the com-
monly cited patient-related factors.
A few studies have suggested an association between sleep 
disturbance and CINV (2). The gastrointestinal system is closely 
linked with the central nervous system. A community study 
showed that overall gastrointestinal symptoms including nausea 
are related to sleep disturbances (3). Another study showed that 
nausea is associated with anxiety and depression. In the case of 
motion sickness, sleep deprivation can enhance susceptibility. 
Therefore, sleep and mood can be related to CINV. Moreover, 
since depression is prevalent in cancer patients, insomnia is 
three times more common than the 7.0% to 9.5% rate in the 
general population (4).
Whereas the development of antiemetic guidelines has helped 
to control the level of chemotherapy-induced vomiting (CIV), ad-
vances in the treatment of chemotherapy-induced nausea (CIN) 
are more limited. Moreover, CIN has a greater negative effect on 
patients’ daily lives than CIV (3). In this regard, it would be help-
ful to assess the physiological and psychological factors associat-
ed with CIN and CIV in a relatively homogeneous study sample. 
The aim of this study was to investigate QOL and night-time 
sleep of colon cancer patients with middle risk chemotherapy for 
proper antiemetic therapy. 
PATIENTS & METHODS
Study Design and Setting
An open, multicenter, prospective, observational study was 
conducted in 11 general hospitals on Shikoku island in Japan. 
The protocol was approved by the clinical research ethics com-
mittees of all participating centers (TOCMS #1861). This study 
was conducted from April 2014 to March 2017. Clinical staff 
approached potentially eligible patients with colon cancer who 
visited individual departments. All participants provided writ-
ten, informed consent. 
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Patient Selection Criteria
The study enrolled 139 patients aged 35 to 89 years old with 
colorectal cancer. All patients received oxaliplatin or irino-
tecan-based chemotherapy. There were no specific eligibility 
criteria. 
Patients’ characteristics 
The mean age of the patients was 64 (35-89) years, and there 
were 97 male and 42 female patients. Concerning the chemo-
therapy, 90 patients received first-line chemotherapy (oxalipla-
tin / irinotecan / both : 93 / 43 / 3). For antiemetic prophylaxis, a 
5-HT3, granisetron in 48 patients and palonosetron in 91 pa-
tients, was used. Aprepitant was used in 101 patients and not 
used in 38 patients. Stage was II  /  III  /  IV in 19 / 42 / 78 patients 
(Table 1).
Data Collection
Patients who agreed to participate in the study completed a 
questionnaire about CINV and sleep disturbance and returned 
it at their next clinical visit. The questionnaires were sent to the 
University of Tokushima and analyzed. Clinical data (cancer 
stage and treatments received) were obtained from a review of 
medical records.
Nausea, Vomiting, and Appetite loss
Nausea and vomiting were evaluated using self-assessed 
questionnaires. Nausea was considered present if a symptom 
of nausea was present, and vomiting was considered present if 
there was vomiting over a period of 7 days. Appetite loss was 
considered present if there was “half of intake compared with 
ordinary oral intake”, “one-fourth compared with ordinary oral 
intake”, or “Hard to take water and meals”. 
QOL
QOL was evaluated using the SF-36v2, and low QOL was de-
fined as a total score lower than the national standard. 
SF-36v2
The Optum SF-36v2 Health Survey asks 36 questions to 
measure functional health and well-being from the patient’s per-
spective. It is a practical, reliable, and valid measure of physical 
and mental health that can be completed in five to ten minutes. 
We refer to it as a generic health survey because it can be used 
across ages (18 and older), diseases, and treatment groups, as 
opposed to a disease-specific health survey, which focuses on a 
particular condition or disease. Meaningful to patients, clini-
cians, researchers, and administrators across the health care 
spectrum, the SF-36v2 has a variety of applications including : 1. 
measuring health improvement or decline ; 2. predicting medical 
expenses ; 3. assessing treatment effectiveness ; and 4. compar-
ing disease burden across populations.
The SF-36v2 provides scores for each of the eight health do-
mains and psychometrically-based physical component summa-
ry (PCS) and mental component summary (MCS) scores. Since 
the survey uses norm-based scoring, comparisons can be made 
with the other generic health surveys (SF-12v2 and SF-8). A 
preference-based utility index, called the SF-6D, is also available 
to help understand economic benefit. Multiple modes of admin-
istration are offered, including online, PDA, and more. The SF-
36v2 is available in more than 170 translations for both standard 
four-week and acute one-week recall periods. This questionnaire 
consists of Physical functioning, Role physical, Bodily pain, 
General health, Vitality, Social functioning, Role emotional, and 
Mental health scores (5). 
Sleep-Related Factors
Sleep quality and disturbance were assessed using the Pitts-
burgh Sleep Quality Index (PSQI), and a cut-off value of 6 was 
used to define significant poor sleep quality, which has been 
suggested for physically ill patients (6). The evaluation was done 
7 days after the beginning of chemotherapy. 
Pittsburgh Sleep Quality Index (PSQI)
The PSQI is a self-administered questionnaire to assess sub-
jective sleep quality during the previous month. The self-rated 
items of the PSQI generate seven component scores (range of 
subscale scores, 0-3) : sleep quality ; sleep latency ; sleep dura-
tion ; habitual sleep efficiency ; sleep disturbance ; use of sleep-
ing medication ; and daytime dysfunction. The sum of these 
seven component scores yields one global score of subjective sleep 
quality (0-21), with higher scores representing poorer subjective 
sleep quality. The psychometric properties of the PSQI have been 
confirmed by previous studies (7). 
Data Analysis
Bivariate correlations among nausea, vomiting, and sleep-re-
lated factors were evaluated. Univariable logistic regression 
analyses were conducted to examine variables associated with 
nausea and sleep disturbance. Statistical analyses were carried 
out using the JMP 10 statistical software package (SAS Insti-
tute Inc, Tokyo, Japan). Student’s t-test was used to compare 
continuous variables. A P-value of less than 0.05 was considered 
significant. 
RESULTS
Prevalence of nausea, vomiting, and appetite loss 
The prevalence of nausea was 48.9% (68 / 139). The degree of 
the nausea was slight / moderate / severe in 51 / 11 / 6 patients, and 
12 patients reported vomiting. Appetite showed no change / slight-
ly decreased / half / one-fourth / none in 51 / 34 / 33 / 6 / 7 patients.
QOL
The SF-36v2 consists of 8 parts, and the physical components 
consist of physical functioning, role physical, and bodily pain. 
The mental factor consists of role emotional and mental health. 
Both physical and mental factors consist of social functioning, 
general health perceptions, and vitality. For the physical com-
ponent summary (PCS) score, mental component summary 
(MCS) score, and the role-social component score (RCS), there 
was a significant difference in the MCS and RCS scores (Fig-
ure 1) (MCS : nausea(+) vs nausea(-), 46.4 ± 1.1 vs 54.1 ± 1.1 
p < 0.01 ; RCS : nausea(+) vs nausea(-), 33.1 ± 2.1 vs 41.6 ± 2.1 
p < 0.01). 
Table 1.　Patient’s characteristics
Factor n = 139
Age 64 (35-89)
Gender (M / F) 97 / 42
Line (first / beyond second) 90 / 49
Regimen (Oxaliplatin / Irinotecan / Both) 93 / 43 / 3
5-HT3 (Granisetron / Palonosetron) 48 / 91
Aprepitant (+ / -) 101 / 38
Stage (II / III / IV) 19 / 42 / 78
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Sleep disturbance 
Although there was no significant difference, there was a pos-
sible correlation between sleep disturbance and nausea (Figure 
2). 
Risk Factors for QOL and sleep disturbance
With an MCS cut-off score of 50, the patients were divided into 
two groups, and nausea was significantly correlated with a low 
MCS score (Table 2). Furthermore, patients were divided into 
two groups by a PSQI cut-off score of 6, and sleep disturbance 
was correlated with old age and second-line chemotherapy. 
Nausea was correlated with sleep disturbance, but it was not 
significant (Table 3). 
Effect of antiemetic prophylaxis
There was no significant difference in the prevention of nau-
sea and vomiting with and without aprepitant. 
 
DISCUSSION
The present study showed that the incidence of nausea was 
48.9%, but about 75% of it was low grade. Furthermore, the in-
cidence of vomiting was about 10%. Despite the administration 
of optimal antiemetic prophylaxis, appetite loss (half or more) 
was observed in about 35% of patients. Nausea was found to be 
positively correlated with the MCS and RCS scores, and nausea 
had a negative effect on sleep. A low MCS score was significantly 
correlated with nausea. The factors associated with poor night-
time sleep were older age (> 70 years old) and chemotherapy line 
(more than second-line).
The associations between the presence of nausea and MCS 
and RCS scores were remarkable, and the prevention of nausea 
is very important to maintain the QOL of patients on chemother-
apy. Interestingly, the present study showed a strong negative 
impact on patients’ QOL with the presence of significant nausea 
or vomiting and their duration. In the present study, nausea had 
a higher impact on patients’ QOL than vomiting, and nausea had 
a negative effect not only on the MCS, but also on the RCS. This 
finding is crucial, because one of the goals of chemotherapy regi-
mens is to maximize the doses, albeit with shorter duration reg-
imens (8). Therefore, the duration of CINV should be taken into 
account when antiemetic prophylactic treatment is prescribed. 
As shown in the present study, the development of significant 
nausea has an important negative impact on patients’ QOL.
The present study examined the relationship between sleep 
and nausea in colorectal cancer patients. It was found that nau-
sea was related to poor sleep quality, although not significantly, 
especially for elderly patients and patients with over second-line 
chemotherapy. Doctors who treat patients with chemotherapy 
take every effort to reduce the incidence of nausea. Prevention of 
nausea improves the quality of sleep and furthermore increases 
the QOL of patients on chemotherapy. As far as we are aware, 
few reports have examined sleep and nausea in colorectal can-
cer patients. In breast cancer patients, poor sleep quality was 
Figure 1.　The effect of nausea on the component summary scores : 
physical component summary (PCS), mental component summary 
(MCS), and role-social component score (RCS).
Figure 2.　The effect of nausea on night-time sleep (PSQI score).




< 50 (n = 64) > 50 (n = 75)
Age 63.5 65.3 n.s.
Gender M / F 41 / 23 56 / 19 n.s.
Line First / Second 45 / 19 45 / 30 n.s.
Nausea yes / no 43 / 21 25 / 50 < 0.01
Vomit yes / no 9 / 42 3 / 49 0.06
Apreptant yes / no 44 / 20 57 / 18 n.s.




< 6 (n = 69) > 6 (n = 70)
Age 62.4 66.5 < 0.05
Gender M / F 50 / 19 47 / 23 n.s.
Line First / Second 48 / 21 38 / 32 < 0.05
Nausea yes / no 29 / 40 39 / 31 0.1
Vomit yes / no 7 / 40 5 / 51 n.s.
Apreptant yes / no 49 / 20 52 / 18 n.s.
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associated with CINV after the first cycle of chemotherapy. 
Because an emesis response in the previous cycle is the stron-
gest risk factor for CINV (9), clinicians should emphasize the 
management of poor sleep quality before a vicious cycle starts.
The association between poor sleep quality and CINV may be 
alternatively explained by autonomic nervous system (ANS) dys-
function. Greater reactivity and arousal of the ANS have been 
reported in individuals with insomnia (10). Insomnia-related 
ANS arousals were demonstrated as decreased high-frequency 
power and increased low-frequency power in heart rate vari-
ability analyses (11). Similarly, chemotherapy-induced adverse 
effects including CINV and fatigue are reportedly related to in-
creased activity and / or reactivity of the ANS. The present study 
showed that age and chemotherapy regimen line were predictors 
of sleep disturbance. In addition to the fact that sleep problems 
are more frequent in cancer patients, younger age and female sex 
are predisposing factors for insomnia (12-14). On the other hand, 
in the general population, older age is a predisposing factor for 
insomnia. Thus, the risk factors are controversial.
With respect to sleep disturbances, there are various aberra-
tions that can occur in, for example, including total sleep time, 
sleep-onset latency, nocturnal awakenings, and wake time after 
sleep onset, as well as daytime napping with a circadian rhythm 
perceived sleep disturbance and use of sleep aids. The detailed 
reasons for a sleep disturbance should always be investigated 
(15).
Because newer agents such as aprepitant are not always effec-
tive at controlling CINV, olanzapine, a serotonin-dopamine re-
ceptor antagonist, has been suggested as a treatment for CINV. 
A recent study showed that olanzapine improved global health 
status, emotional functioning, and insomnia in cancer patients, 
in part by reducing the incidence of delayed CINV. The present 
study showed that poor sleep quality was significantly associated 
with CINV. Another psychiatric medication, mirtazapine, a nor-
adrenergic and specific serotonergic antidepressant, improves 
symptoms of nausea and insomnia in cancer patients (16). Sed-
ative effects of olanzapine and mirtazapine might help the sleep 
problem to prevent CINV, in addition to stimulating appetite. 
These psychoactive drugs may act through receptors other than 
serotonin 5-HT3, such as histamine-1 or serotonin 5-HT2C. As 
there was a significant difference concerning chemotherapy line 
between PSQI score, the treatment with olanzapine and mir-
tazapine may be considered from the first line.
First, patients feel the nausea, the nausea affects sleep, and 
the disturbance of sleep affects the patient’s mood. As a result, 
the incidence of nausea will increase. To break the vicious cycle, 
antiemetic prophylaxis is important (17, 18).
The use of aprepitant as secondary antiemetic prophylaxis 
for patients with oxaliplatin-based chemotherapy was effective. 
Aprepitant could be used as salvage antiemetic therapy in col-
orectal cancer patients receiving oxaliplatin-based chemother-
apy. However, aprepitant did not contribute to decreasing the 
incidence of nausea and vomiting. In a previous study, aprepitant 
had a positive effect to prevent nausea. This was an observation-
al study, it was not performed as a randomized, controlled study, 
the number in each group was different, and so on, resulting in 
no significant difference with aprepitant use (1). 
The present study has several limitations. First, this study 
was performed with a single arm, and the number of patients 
enrolled was too small. Second, the period of the questionnaire 
was only 7 days and at only one point in time. Third, although 
the psychological condition affects this result, we didn’t check the 
patient’s psychological condition. Finally, this study was conduct-
ed in several institutions with different chemotherapy regimens, 
and chemotherapy regimens may have an effect. 
CONCLUSION
Nausea affects the QOL and night-time sleep of colon cancer 
patients with middle risk chemotherapy, so that proper antiemet-
ic therapy is needed. 
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